Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
January 10, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR CEO, Jean-Paul Clozel, to update on how Idorsia is being adapted for sustainable value creationThe company is focused on extending the cash runway beyond...
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
January 10, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR CEO, Jean-Paul Clozel, to update on how Idorsia is being adapted for sustainable value creationThe company is focused on extending the cash runway beyond...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
November 03, 2023 17:30 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
November 03, 2023 17:30 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment...
Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
October 24, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad-hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz – 24. Oktober 2023 Idorsia Ltd (SIX: IDIA) gab heute die Finanzergebnisse für die ersten neun Monate 2023 bekannt. Business Highlights ...
Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
October 24, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 24, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2023. Business...
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
October 23, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – October 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that it is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023, a...
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
October 23, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – October 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that it is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023, a...
Idorsia reacquires the world-wide rights to aprocitentan
September 06, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with...
Idorsia reacquires the world-wide rights to aprocitentan
September 06, 2023 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with...